Corneal Consultants of Colorado, P.C Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2020
NCT04401865
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Colorado Eye Consultants/Cornea Consultants of Colorado | Colorado Eye Consultants/Corneal Consultants of Colorado

Active Ingredients

Drugs in Phase 2 Trials (1)

riboflavin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Corneal Diseases (Phase 2)

Dilatation, Pathologic (Phase 2)

Keratoconus (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1